Lamivudine therapy for hepatitis B infection

Scandinavian Journal of Gastroenterology, Supplement

Volumn 33, Issue 34, 1999, Pages 76-81

  Dusheiko, G ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Liver Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINO ACID; AMINOTRANSFERASE; ANTIVIRUS AGENT; CIRCULAR DNA; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADVERSE DRUG REACTION; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; HEPATITIS B; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS REPLICATION; VIRUS RESISTANCE; BLOOD; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B VIRUS; IMMUNOLOGY; REVIEW; TREATMENT OUTCOME; VIROLOGY;

DNA, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TRANSAMINASES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0032611193     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995;35:1174-80.
2. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996;40:1514-9.
3. Lai CL, Ching CK, Tung ARM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4.
4. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
5. Lai CL, Liaw YF, Leung NWY, et al. Twelve months of lamivudine (100 mg od) therapy improves liver histology: results of a placebo-controlled multicentre study in Asia [Abstract]. J Hepatol 1997;26:79.
6. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-5.
7. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62:1456-62.
8. AI Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926-8.
9. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;63:393-6.
10. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997;64:1624-7.
11. Ling R, Mutimer D, Ahmed N, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
12. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
13. Honkoop P, Niesters HGM, De Man RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B - Incidence and patterns. J Hepatol 1997;26:1393-5.
14. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
15. Smith RA, Remington KM, Lloyd RM Jr, Schinazi RF, North TW. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol 1997;71:2357-62.
16. Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [( - )-beta-L-2′, 3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996;40:1957-60.
17. Moraleda G, Saputelli J, Adrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.
18. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996;24:991-5.
19. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
20. Zeuzem S, De Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-6.
21. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 1996;93:4398-402.